Dogs afflicted with cancer may soon have increased access to the diagnostics and precision medicine currently available in human medicine. California-based One Health Company has secured $10 million in new financing to help accelerate the expansion of its flagship product, FidoCure. The next-generation sequencing technology aims to “bridge the gap” between canine and human cancer therapeutics by making precision medicine accessible for dogs. The additional series-A funding, contributed by Polaris Partners and Borealis Ventures, will help the company expand its research to better understand human cancers and how therapies used can be applied to canine medicine, One Health Company says. Approximately one in four of the 90 million dogs living in American households will develop cancer at some point in their lives, according to the company. “Cancer care for dogs has not changed much in the last 30 years, but human cancer care has tremendously advanced, especially in the field of precision medicine,” says One Health Company’s cofounder and CEO, Christina Lopes. “Using the same advanced cancer diagnostics and precision medicine currently on the market and approved by FDA for people, we are bringing cancer care for dogs. And, when we open access to precision cancer treatments for our furry friends, we build data that helps advance human oncology research and treatment.” FidoCure is currently used by more than 200 veterinarians across the U.S. For more, click here.
